Gut Microbiome and Immune Checkpoint Inhibitors in Cancer Treatment
Author Information
Author(s): Sona Ciernikova, Aneta Sevcikova, Maria Novisedlakova, Michal Mego
Primary Institution: Biomedical Research Center of the Slovak Academy of Sciences
Hypothesis
The composition of the gut microbiome influences the efficacy and toxicity of immune checkpoint inhibitors in solid tumors.
Conclusion
Modulating the gut microbiome can enhance the effectiveness of immune checkpoint inhibitors and reduce treatment-related adverse events.
Supporting Evidence
- Specific gut bacteria can predict responses to immunotherapy.
- Probiotics and dietary changes can improve treatment outcomes.
- Patients with diverse gut microbiomes tend to respond better to cancer treatments.
Takeaway
The bacteria in our gut can help cancer treatments work better and make side effects less severe.
Methodology
This review summarizes findings from various studies on the gut microbiome's role in cancer immunotherapy.
Potential Biases
Potential biases in the studies reviewed may affect the conclusions drawn.
Limitations
The review is based on existing studies, which may have varying methodologies and sample sizes.
Participant Demographics
The review includes studies on patients with various solid tumors, including melanoma and lung cancer.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website